A detailed history of Baker Bros. Advisors LP transactions in Arvinas, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 405,576 shares of ARVN stock, worth $9.81 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
405,576
Holding current value
$9.81 Million
% of portfolio
0.11%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.66 - $32.73 $9.6 Million - $13.3 Million
405,576 New
405,576 $9.99 Million
Q3 2023

Nov 14, 2023

BUY
$19.64 - $28.21 $8.12 Million - $11.7 Million
413,481 New
413,481 $8.12 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.29B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.